Research Findings Present Solutions For Knee Degradation

At Choiceone, one of our primary goals is to provide patients suffering from articular cartilage defects with innovative and effective choices to restore their health. This is especially important for those facing knee issues, as traditional solutions can often bring new challenges.

The use of Wharton’s Jelly Stem Cell Matrix therapy has produced staggering results for patients with articular cartilage defects. While tissue allografts do not treat, cure, or prevent any disease, structural tissue allografts are routinely used to replace missing or damaged tissue in the body, offering patients a minimally invasive option to address their concerns.

In the United States, 33 million adults are living with osteoarthritis (OA), a number expected to nearly double within the next decade. Adults aged 45 to 64 will represent a third of all OA cases in that timeframe. Untreated osteoarthritis not only impacts mobility and quality of life but can also shorten a patient’s lifespan by six to seven years.

For many, total knee arthroplasty (TKA) is a common solution, but it comes with significant monetary and physical costs. TKA procedures range from $12,400 to $16,000, and recovery can take anywhere from six months to a year. Those with desk jobs may require four to six weeks off work, while physically demanding jobs may require up to three months before resuming full activity. Other commonly used options, such as intra-articular corticosteroid injections, come with their own risks, including accelerated OA progression, subchondral insufficiency fractures, and rapid joint destruction with bone loss. These complications contribute to job-related losses estimated at $3.4 to $13.2 billion annually.

At Choiceone, we understand these challenges and offer a better alternative to TKA and corticosteroid injections. Through Wharton’s Jelly Stem Cell Matrix therapy, we aim to provide relief to patients while supporting the regeneration of damaged tissue.

Dr. Javier Carles, M.D., from Palmetto Clinics of the Carolinas, shares his experience:
“Utilizing multiple Wharton’s Jelly-derived products over the last five years, I have seen positive patient results.”

As research continues, the applications for Wharton’s Jelly therapy are expanding, supported by numerous peer-reviewed studies and compelling patient outcomes. “The proof is in patients’ results, including reevaluations, post-application progress, and x-rays,” added Dr. Carles.

Choiceone is proud to offer this cutting-edge therapy to help patients find relief from joint pain and tissue damage, providing a path toward better health and restored mobility.

Schedule an appointment with our physician at Choiceone to see if you qualify for Wharton’s Jelly Stem Cell Matrix Injections.